Top

Published in:

Open Access 16-10-2023 | Human Immunodeficiency Virus | Original Research

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study

Authors: Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long

Published in: Infectious Diseases and Therapy | Issue 11/2023

Abstract

Introduction

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG + 3TC) are well tolerated and effective in clinical trials. This study aimed to evaluate the safety and efficacy of these two schemes in a real-world setting and to obtain the first dataset for switching to BIC/FTC/TAF and DTG + 3TC in a Chinese population.

Methods

This retrospective single-center cohort study in China included participants who switched to DTG + 3TC or BIC/FTC/TAF between January 2020 and February 2023. The main endpoint was the proportion of participants with HIV-1 RNA levels of ≥ 50 copies/mL. Safety, tolerance, and the incidence of low-level viremia (LLV) were evaluated.

Results

A total of 525 participants were included, 454 of whom were included in the PP analysis. At week 48, the proportions of participants with HIV-1 RNA ≥ 50 copies/mL were 4.4% (10/225) for DTG + 3TC and 6.1% (14/229) for BIC/FTC/TAF; virological efficacy did not differ significantly between the two groups. Consistent results were obtained in an intent-to-treat (ITT) analysis. The incidences of LLV were 3.6% (7/193) and 4.9% (10/206), respectively. During the study, none of the participants stopped taking drugs because of a lack of efficacy or adverse reactions.

Conclusions

Both regimens are well tolerated and effective for switching HIV-1 infection therapy. However, the detection of genotypic drug resistance should be considered when baseline virological non-suppression is observed.

Available only for authorised users

Chen LY, Sun HY, Chuang YC, et al. Patient-reported outcomes in virally suppressed people living with HIV after switching to co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023;56:575–85. https://doi.org/10.1016/j.jmii.2023.01.015.CrossRefPubMed

Patel R, Evitt L, Mariolis I, et al. HIV treatment with the two-drug regimen of dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review. Infect Dis Ther. 2021;10:2051–70. https://doi.org/10.1007/s40121-021-00522-7.CrossRefPubMedPubMedCentral

Trujillo-Rodríguez M, Muñoz-Muela E, Serna-Gallego A, et al. Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. Clin Microbiol Infect. 2022;28:1151.e9–1151.e16. https://doi.org/10.1016/j.cmi.2022.02.041.CrossRefPubMed

da Cunha J, Maselli LMF, Stern ACB, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs. World J Virol. 2015;4:56–77. https://doi.org/10.5501/wjv.v4.i2.56.CrossRefPubMedPubMedCentral

Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol. 2018;9:705. https://doi.org/10.3389/fendo.2018.00705.CrossRef

Yang X, Fu Y, Xie X, et al. Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China. Expert Rev Anti Infect Ther. 2022;20:1501–8.CrossRefPubMed

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV infection; 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed 24 Sep 2021

European AIDS clinical society [EACS guidelines]. Version 11.0; 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf. Accessed 7 Nov 2021.

Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for the treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel. JAMA. 2023;329:63–84. https://doi.org/10.1001/jama.2022.22246.CrossRefPubMed

10.

Acquired Immunodeficiency Syndrome and Hepatitis C. Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome, 2021 edn. Chinese J AIDS & STD 2021;27(11):1182–1201.

11.

Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74:739–45. https://doi.org/10.1093/jac/dky467.CrossRefPubMed

12.

Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicenter, double-blind, randomized, non-inferiority, phase 3 trials. Lancet. 2019;393:143–55. https://doi.org/10.1016/S0140-6736(18)32462-0.CrossRefPubMed

13.

Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71:1920–9. https://doi.org/10.1093/cid/ciz1243.CrossRefPubMedPubMedCentral

14.

Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for the initial treatment of HIV-1 infection: week 96 results from a randomized, double-blind, multicenter, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355–63. https://doi.org/10.1016/S2352-3018(19)30077-3.CrossRefPubMed

15.

Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulation of bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for the initial treatment of HIV-1 infection: week 96 results from a randomized, double-blind, multicenter, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e364–72. https://doi.org/10.1016/S2352-3018(19)30080-3.CrossRefPubMed

16.

Daar ES, Dejesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in adults with virologically suppressed HIV-1:48 week results of a randomized, open-label, multicenter, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347–56. https://doi.org/10.1016/S2352-3018(18)30091-2.CrossRefPubMed

17.

Molina JM, Ward D, Brar I, et al. Switching from dolutegravir plus abacavir and lamivudine to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV-1:48 week results of a randomized, double-blind, multicenter, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357–65. https://doi.org/10.1016/S2352-3018(18)30092-4.CrossRefPubMed

18.

Du X, Peng W, Fu Q, Ma Q, Zhu Z, Li T. A review of the clinical pharmacokinetic and pharmacodynamic profiles of select antiretrovirals: focus on differences among Chinese patients. Pharmacotherapy. 2019;39:1179–89. https://doi.org/10.1002/phar.2333.CrossRefPubMed

19.

Center for STD and AIDS Prevention and Control, Chinese Center for Disease Control and Prevention. National Handbook of Free Antiviral Therapy for AIDS. Version 3. Beijing: People’s Health Publishing House, 2016.

20.

Chen GJ, Sun HY, Chen LY, et al. Low-level viremia and virologic failure in people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. Int J Antimicrob Agents. 2022;60:106631. https://doi.org/10.1016/j.ijantimicag.2022.106631.CrossRefPubMed

21.

Llibre JM, Brites C, Cheng CY, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3-or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial. Clin Infect Dis. 2023;18;76(4):720–9.

22.

Rojas J, de Lazzari E, Negredo E, et al. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021;8:e463–73. https://doi.org/10.1016/S2352-3018(21)00100-4.CrossRefPubMed

23.

Ding H, Xu J, Liu J, et al. Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: a prospective cohort study. HIV Med. 2022;23(Suppl 1):64–71. https://doi.org/10.1111/hiv.13250.CrossRefPubMed

24.

Navarro J, Caballero E, Curran A, et al. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment. Antivir Ther. 2016;21:345–52. https://doi.org/10.3851/IMP3023.CrossRefPubMed

25.

Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18:188–97. https://doi.org/10.1016/S1473-3099(17)30681-3.CrossRefPubMed

26.

Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69:2145–52. https://doi.org/10.1093/cid/ciz129.CrossRefPubMedPubMedCentral

27.

An J, Lao Y, Tang S, Lou J, Li T, Dong X. The impact of low-level viraemia on virological failure—results from a multicenter HIV antiretroviral therapy cohort study in Yunnan. China Front Med. 2022;9:939261. https://doi.org/10.3389/fmed.2022.939261.CrossRef

28.

Santoro MM, Armenia D, Teyssou E, et al. Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study. J Glob Antimicrob Resist. 2022;31:52–62.CrossRefPubMed

29.

Degroote S, Vanherrewege S, Tobback E, et al. Favorable metabolic outcomes 48 weeks after switch to DTG/3TC. https://www.croiconference.org/abstract/favorable-metabolic-outcomes-48-weeks-after-switch-to-dtg-3tc/. Accessed 24 Aug 2023

Title: Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
Authors: Lin Gan
Xiaoxin Xie
Yanhua Fu
Xiaoyan Yang
Shujing Ma
Linghong Kong
Chunli Song
Yebing Song
Tingting Ren
Hai Long
Publication date: 16-10-2023
Publisher: Springer Healthcare
Keywords: Human Immunodeficiency Virus
Tenofovir
Lamivudine
Published in: Infectious Diseases and Therapy / Issue 11/2023
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-023-00879-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2023

The Causal Impact of the Gut Microbiota on Respiratory Tuberculosis Susceptibility

The Present and Future Aspects of Life-Long Pertussis Prevention: Narrative Review with Regional Perspectives for Türkiye

Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies

Disease Burden of Meningitis Caused by Streptococcus pneumoniae Among Under-Fives in China: A Systematic Review and Meta-analysis

Evaluation of Different Blood Culture Bottles for the Diagnosis of Bloodstream Infections in Patients with HIV

Mutations in Coding and Non-Coding Regions in Varicella-Zoster Virus Causing Fatal Hemorrhagic Fever Without Rash in an Immunocompetent Patient: Case Report

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials